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The current status of valve replacement was reviewed 
by analyzing six groups of 100 consecutive patients, each 
receiving the standard Carpentier-Edwards biopros•
thesis, the Starr-Edwards valve or the Bjork-Shiley valve 
in the mitral or aortic position and operated on by the 
same surgeons in the same institution during an identical 
time frame. Data were evaluated for valve failure, re•
operation, thromboembolism and valve-related deaths. 
Long-term results up to 9 years showed the superiority 
of bioprostheses over mechanical valves in terms of valve•
related deaths and thromboembolic and anticoagulant 
complications for a similar rate of valve failure. Per•
sistent drawbacks associated with valvular biopros•
theses, namely, trans valvular gradients, limited dur•
ability and tissue calcification in young patients, led to 
continual improvements in valve design and preservation 
techniques and the development of the third generation 
Carpentier-Edwards bioprosthesis: the supraanular 
porcine valve and pericardial valve. The supraanular 
Since the first glutaraldehyde-preserved biologic valve was 
introduced in 1968 (I), this method of valve replacement 
has been widely used because of specific advantages over 
mechanical valves. Several drawbacks became apparent, 
however, as the use of the valves became more widespread. 
Therefore, improvements were introduced leading to a sec•
ond generation and subsequently a third generation of bio•
prostheses. The purpose of this paper is to introduce the 
third generation of the Carpentier-Edwards bioprosthesis by 
pointing out the research and developmental factors that 
influenced its design and production and the preliminary 
results obtained at the Broussais Hospital in Paris during 
the past 4 years. 
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porcine valve was designed with the aim of decreasing 
the transvalvular gradient, decreasing turbulence, in•
creasing longevity and decreasing calcification. The per•
icardial valve was designed with the aim of improving 
hemodynamics in small-sized orifices, improving mount•
ing techniques to avoid fixation sutures at the commis•
sures, achieving a flexible stent and improving 
preservation. 
Between July 1980 and October 1984, there were 391 
supraanular porcine and 61 pericardial valves im•
planted. The supraanular valves were used for three 
purposes: isolated aortic, isolated mitral and mitral valve 
replacement associated with tricuspid anuloplasty. The 
pericardial valves were used for isolated aortic valve 
replacement. Short-term results (1 to 4 years) are pre•
sented concerning the clinical use of these third gener•
ation bioprostheses. 
(J Am Coli CardioI1985;6:1149-54) 
Current Status of Valve Surgery 
Two studies by one of us (P.P.) of long-term results 
obtained with the second generation bioprosthesis are pre•
sented. The data compare the standard Carpentier-Edwards 
bioprosthesis with the Starr-Edwards and Bjork-Shiley me•
chanical valves over a 7 year period between 1974 and 1980 
in relation to valve failure, reoperation, thromboembolism 
and valve-related deaths in six groups of 100 consecutive 
patients operated on in the same institution by the same 
surgeons during an identical time frame. We used this ap•
proach rather than collating data from various centers, a 
procedure in which data can be selected to illustrate a par•
ticular point of view, because we believe that this protocol 
is the only scientifically valid one for a retrospective study. 
Aortic Valve Replacement 
Three groups of 100 consecutive patients with aortic valve 
replacement were operated on between 1974 and 1978 and 
underwent long-term evaluation. The duration of follow-up 
was 5 to 9 years (mean 6). The cumulative follow-up time 
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was 1,638 patient-years. During this period, more than 4,500 
valves were implanted in our center. Follow-up study was 
performed from January to April 1984 (2). 
Valve failure. In conformance with the Stanford defi•
nition, valve failure was defined as encompassing all valve•
related complications including confirmed hemodynamic 
dysfunction, periprosthetic leak, thromboembolism, throm•
botic valvular occlusion and endocarditis prompting reo•
peration or causing death. The incidence of valve failure at 
the end of 8 years was 20% in the bioprosthesis group, 13% 
in the Starr-Edwards group and 12% in the Bjork-Shiley 
group. These differences were not statistically significant. 
However, the 10 cases of valve failure in the bioprosthesis 
group were responsible for a 20% mortality rate (2 deaths) 
in contrast to a rate of 73 and 78%, respectively, in the two 
other groups of prosthetic valve failure. 
Reoperation. The actual risk of reoperation at 8 years 
was 16% in the bioprosthesis group, 5% in the Starr-Ed•
wards group and 2% in the Bjork-Shiley group. The dif•
ference between the bioprosthesis and the Bjork-Shiley group 
was significant. All cases of valve failure in the bioprosthesis 
group were gradual and allowed for reoperation, whereas 
catastrophic events precluding operation were more frequent 
in the two mechanical prosthesis groups. 
Thromboembolism. On an actuarial basis, 95% of pa•
tients in the bioprosthesis group were free of thromboem•
bolism at 8 years compared with 81 and 84%, respectively, 
in the Starr-Edwards and Bjork-Shiley groups. This differ•
ence was statistically significant, and furthermore, the 
thromboembolic episodes in the patients with a bioprosthesis 
were transient whereas patients in the other two groups 
remained severely disabled after these episodes. 
Valve-related deaths. The incidence of valve-related 
deaths at 8 years was 4% in the bioprosthesis group and 
13% in both other groups. There was a statistically signif•
icant difference between the bioprosthesis and mechanical 
valve groups. At least half of the valve-related deaths in the 
mechanical valve groups were due to thromboembolic 
complications. 
Mitral Valve Replacement 
A second, similar study was performed on mitral valve 
replacement for mitral insufficiency (3). Again the period 
studied was 1974 to 1978 and three groups of 100 consec•
utive patients with a bioprosthesis and Starr-Edwards and 
Bjork-Shiley valves were compared. The duration offollow•
up was 7 years with a cumulative follow-up time of 2,058 
patient-years. 
Valve failure. The incidence of valve failure at 7 years 
was 20% for the bioprosthesis and 21 and 25% for the Starr•
Edwards and the Bjork-Shiley valves, respectively, but this 
difference was not statistically significant. At 7 years, only 
five patients with a bioprosthesis had undergone reoperation 
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for intrinsic alteration of the valve. The most frequent cause 
of valve failure in the mechanical valve group was a throm•
boembolic complication. 
Reoperation. The actuarial risk of reoperation was 20% 
in the bioprosthesis group compared with 8% in the other 
two groups; this difference was not significant. The com•
parison of reoperation and valve failure underlines the fact 
that some catastrophic events that did not allow for reo•
peration occurred in the mechanical valve groups. 
Thromboembolism. Of patients with a bioprosthesis, 
94% were free of thromboembolic complications at 7 years 
compared with 70 and 68%, respectively, in the mechanical 
valve groups; this difference was statistically significant. 
Valve-related deaths. The incidence of valve-related 
deaths was 8% in the bioprosthesis group compared with 
18% in each of the two other groups. Although this differ•
ence is not significant using the two-tailed t test, it was 
noted that thromboembolic complications were the main 
cause of death in the mechanical valve groups. We con•
cluded from these studies that the bioprosthesis was superior 
to the mechanical valves in terms of valve-related deaths 
and thromboembolic and anticoagulant complications for a 
similar rate of valve failure. 
The Supraanular Bioprosthesis 
In light of such excellent results with the standard Car•
pentier-Edwards valve, what were the pending problems 
with this bioprosthesis? There were three: transvalvular gra•
dients with small valve sizes, fatigue lesions (20% at 10 
years) and calcification (50% at 4 years in children). For 
these reasons, the third generation Carpentier-Edwards su•
praanular valve was developed and tested with the following 
aims: decreasing the transvalvular gradient, decreasing tur•
bulence around the valve, increasing valve longevity and 
decreasing the incidence of calcification. 
Approach 
Because transvalvular gradients result mainly from the 
impedance caused by the stent and the aortic remnant sup•
porting the cusps, valve design was modified so as to implant 
the valve in the supraanular position. The concept was to 
implant the stent and the aortic remnant above rather than 
inside the anulus of the aortic root so that a larger valve 
could be used. Only the cusps of the supraanular porcine 
valve remain exposed to the blood column. Hemodynamics 
through the valve were also improved by reducing the amount 
of synthetic material and optimizing sewing anulus design. 
The supraanular valve was developed according to these 
specifications and the hemodynamic performance was tested 
in vitro by comparing the new valve with current aortic 
valves. Other areas of research focused on 1) optimizing 
flexibility to decrease loading shock on the commissures 
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and base of the cusps and to improve hemodynamics, 2) 
providing a supraanular configuration to allow supraanular 
positioning of the valve, 3) improving valve design to reduce 
turbulence, and 4) developing better methods of tissue 
preservation. 
The stent height of the supraanular porcine valve in the 
mitral position was decreased so as to minimize protrusion 
into the ventricular cavity and left ventricular outflow tract. 
The protrusion of the struts over the sewing ring was further 
decreased in the mitral model by a special configuration of 
the sewing ring. Strut protrusion over the sewing ring varies 
from 10 mm for the 25 mm valve to 13 mm for the 35 mm 
valve, which corresponds to an effective protrusion of 8 to 
10 mm within the ventricular cavity if the 2 to 3 mm thick•
ness of the mitral valve anulus is taken into consideration. 
Comparison between the current model and the supraanular 
valve shows a 30% decrease in intraventricular protrusion 
of the current valve (Fig. 1). In vitro hydrodynamics, com•
paring size 21 valves of the Starr-Edwards, Bjork-Shiley, 
St. Jude Medical and supraanular Carpentier-Edwards types, 
show a smaller pressure gradient across the supraanular 
valve at virtually all flow rates with the difference becoming 
greater as the flow rate increases (Fig. 2). 
Tissue Preservation 
Improved tissue preservation is important to increase valve 
longevity. Three areas were selected for improvement: 1) 
the shipping time, which was decreased to an average of 
32 hours under uniform and optimal conditions, 2) fixation 
of the valves at low compression pressures of 4 mm Hg, 
and 3) the shipping medium, which was a cold buffered 
solution with a pH of 7.4 and temperature range of 0 to 
6°C. Shipping conditions and handling of the valves have 
become increasingly difficult in the previous 6 years because 
of the necessity for commercial laboratories to accommodate 
an increasing demand. Availability of adequately sized pigs 
began to be insufficient to cover the needs, which can be 
20 times the number of valves produced because of strict 
criteria in selection and controls. Pig hearts were therefore 
Figure 1. The supraanular bioprosthetic valve in the mitral po•
sition. Comparison between the current model and the second 
generation supraanular porcine valve shows a 30% decrease in 
intraventricular protrusion of the former valve. 
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Figure 2. In vitro hydrodynamic comparison of the size 21 Bjork•
Shiley (B.S.), St. Jude Medical (S.J.M.) and Carpentier-Edwards 
(C.E.) current and supraanular (S.A.V.) valves. 
harvested in countries as far away as the Philippines. His•
tologic and electron microscopic studies performed on valves 
that were shipped and processed according to the newer 
specifications showed that the natural structure of the val•
vular tissue was preserved. There was no alteration of cell 
components of the tissues and the crimp of the collagen 
bundles was preserved. This preservation of histologic struc•
ture resulted in improved durability and fewer variations as 
assessed by in vitro testing of millions of cycles in a pulse 
duplicator. In earlier models, there was wide variation in 
durability not only between valves of different laboratories 
but also between valves from the same laboratory. Fatigue 
testing of the supraanular valve compared with current por•
cine valves demonstrated a decreased number of variations 
and improved average durability (Fig. 3). 
Calcification 
As shown both experimentally and clinically, calcifica•
tion results from various factors. Some are associated with 
the valve itself, such as turbulence, tissue components and 
technique of preservation, and some are associated with the 
patient, such as calcium metabolism and the patient's age 
and diet. Among patient-related factors, only diet could be 
modified by decreasing calcium intake and this was inves•
tigated experimentally by decreasing or increasing calcium 
intake in animals receiving tissue valve leaflets (4). 
Among valve-related factors, turbulence could be de•
creased by improving valve design, that is, increasing the 
surface of the valve orifice by the supraanular concept. 
Tissue components, selection of valves and other valve•
related factors were investigated by evaluating the possible 
influence of age, collagen, source of tissue, dehydration of 
tissue and stabilization of mucopolysaccharides. Finally, 
various techniques of preservation were investigated to elim•
inate or minimize calcification. 
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Figure 3. Fatigue testing of the new supraanular valve (S.A. V.) 
compared with the current porcine valve demonstrates decreased 
variations and improved average durability, indicating improved 
preservation in the current model. 
Among patient-related factors, it is important to avoid 
intravenous calcium; we had one case of calcification 1 
month after implantation in which an adult died of cardiac 
failure after having received intravenous injections of cal•
cium gluconate for 15 days. Excess calcium intake through 
excess consumption of milk or dairy products should be 
avoided, especially in children. Among tissue-related fac•
tors, drying out of leaflet tissue during surgical implantation 
must absolutely be prevented by permanent irrigation with 
saline solution because tissue dehydration after exposure to 
air led to early calcification in the animal model. Other areas 
continue to be under investigation in tissue preparations, 
such as the use of magnesium chloride, nonphosphate buff•
ers, surfactant and polymer incorporation to prevent calci•
fication in children, which remains a considerable challenge. 
Results 
Between July 1980 and October 1984, there were 391 
supraanular valves implanted at our institution. They were 
used for three purposes: isolated aortic, isolated mitral and 
Table 1. Results of Aortic Valve Replacement With the 
Carpentier-Edwards Supraanular Valve in 188 Patients 
Operative mortality rate 
Peri valvular leak 
Thromboembolism 
Cardiac insufficiency 
Miscellaneous 
* Reoperation. 
Patients (no.) 
8 (4.2%) 
3 (2)* 
o 
I (1)* 
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Table 2. Results of Mitral Valve Replacement With the 
Carpentier-Edwards Supraanular Valve in 145 Patients 
Patients (no.) 
Operative mortality rate 6 (4.1%) 
Perivalvular leak 2 (2)* 
Thromboembolism I 
Cardiac insufficiency I 
Miscellaneous 0 
*Reoperation. 
mitral valve replacement associated with tricuspid anulo•
plasty. 
There were 188 aortic valve replacements with an op•
erative mortality rate of 4.2% (8 cases) and a similar com•
plication rate of 4.2% (8 cases). There were three cases of 
bleeding that required reoperation. There was one case of 
cardiac insufficiency and one case of superior vena cava 
syndrome requiring reoperation. There were no cases of 
thromboembolism (Table 1). 
The isolated mitral valve replacement group comprised 
145 patients with an operative mortality rate of 4.1 % (6 
cases). There were seven cases of bleeding and two cases 
of perivalvular leak requiring reoperation. There was one 
case of thromboembolism and one case of cardiac insuffi•
ciency (Table 2). 
The combined mitral valve replacement and tricuspid 
anuloplasty group was composed of 58 patients with a 10.3% 
mortality rate (six cases). Two patients were reoperated on 
for bleeding, two patients had cardiac insufficiency and one 
patient developed mediastinitis (Table 3). 
Pericardial Bioprosthesis 
With the problem of the small aortic root in mind, a new 
pericardial valve was developed with the following aims: 
1) improved mounting to eliminate fixation sutures at the 
commissures, 2) provision of a flexible stent to reduce stress 
at the commissures and base of the cusps, and 3) better 
preservation of tissue to improve valve longevity. 
Table 3. Results of Mitral Valve Replacement Plus Tricuspid 
Anuloplasty With the Carpentier-Edwards Supraanular Valve in 
58 Patients 
Operative mortality rate 
Perivalvular leak 
Thromboembolism 
Cardiac insufficiency 
Miscellaneous 
Patients (no.) 
6 (10.3%) 
o 
o 
2 
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Figure 4. Mounting technique of the pericardial Carpentier•
Edwards bioprosthesis (see text), 
Approach 
Improvement in valve design was the object of numerous 
improvements in the first 10 years. Strut flexibility was an 
important achievement. However, the use of polypropylene 
in stent construction led to the phenomenon of strut creep 
in which the struts became fixed in the valve orifice leading 
to valve distortion, increased gradients and hemorrhagic 
anemia, The use of an Elgiloy wire produced a flexible stent, 
Figure 5. Comparison of Ionescu-Shiley valve (left) and Carpen•
tier-Edwards pericardial valve (right) in a flow tester showing 
greater orifice of the pericardial valve, Some distinguishing char•
acteristics of the two valves are: Ionescu-Shiley: I) rigid stent and 
orifice, 2) suture at commissure tip, 3) pressure fixed on stent; 
Carpentier-Edwards: 1) flexible stent and orifice, 2) no commissure 
suture required, 3) fixed before mounting without pressure, 
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Figure 6. In vitro flow rate of 19 mm SI. Jude Medical (S.J.M.) 
valve and Carpentier-Edwards (C.E.) pericardial valve. 
avoiding the creep phenomenon, and improved exter•
nal/internal ratio by decreasing the thickness of the stent. 
The stent (Fig. 4, top left) was covered with Teflon as was 
the sewing ring (Fig. 4, top right). Cusps were cut out of 
pericardial tissue in appropriate sizes and shapes (Fig_ 4, 
bottom left) and were attached to the stent by sewing them 
in the supraanular position, except at the commissures where 
they were drawn into the top of the struts. This procedure 
eliminated the suture fixation in this area that is present in 
other valves of the new supraanular type (Fig. 4, bottom 
right). Comparison with the Ionescu-Shiley current model 
shows a decrease in strut height and increased internal di•
ameter for valves of the same size. When the valve is com•
pared in a flow tester one can appreciate the greater central 
orifice (Fig. 5). In vitro testing comparing the valve with 
the St. Jude Medical valve showed that the in vitro hydro•
dynamics of the former were better at all flow rates (Fig. 
6). In an in vivo study by Cosgrove et al. (5) from the 
Cleveland Clinic comparing the porcine and pericardial valve, 
the size 25 pericardial valve demonstrated an advantage in 
valve orifice area, greatest at low flow, suggesting a more 
mobile leaflet. 
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Table 4. Results of Aortic Valve Replacement With the 
Carpentier-Edwards Pericardial Valve in 61 Patients 
Operative mortality rate 
Peri valvular lead 
Thromboembolism 
Cardiac insufficiency 
Miscellaneous 
Results 
Patients (no.) 
2 (3.2%) 
o 
o 
o 
The pericardial valve was implanted in 61 patients during 
the same time period of June 1980 to October 1984 with a 
mortality rate of 3.2% (2 cases). Three patients were re•
operated on for bleeding and one patient developed media•
stinitis. There were no cases of perivalvular leak, throm•
boembolism or cardiac insufficiency (Table 4). 
Conclusions 
Our current indications for a bioprosthesis are: adults in 
sinus rhythm, women desiring children, increased risks of 
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anticoagulant agents and patient preference. Contraindica•
tions for a bioprosthesis remain in children, patients with 
renal insufficiency, hyperparathyroidism and early calcifi•
cation of bioprosthesis (less than 6 years after implantation). 
Continuing efforts in valve design and preservation are es•
sential if the already excellent results of tissue valves are 
to be further improved. 
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